Potential for Neoadjuvant and Adjuvant Immunotherapy Approaches in Bladder Cancer

In this downloadable slideset, Matthew I. Milowsky, MD, discusses the current neoadjuvant and adjuvant treatment landscape in bladder cancer and highlights ongoing trials with immune checkpoint inhibitors in this setting.
Format: Microsoft PowerPoint (.ppt)
File Size: 2.12 MB
Released: February 13, 2018


Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)

Produced in collaboration with
Educational grant provided by:
Merck & Co., Inc.
Seattle Genetics

Related Content

From Clinical Care Options (CCO), an on-demand Webcast with Daniel Petrylak, MD, and other experts on optimal treatment for urothelial carcinoma

Matthew I. Milowsky, MD Daniel P. Petrylak, MD Jonathan E. Rosenberg, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Physician Assistants: maximum of 1.25 hours of AAPA Category I (Preapproved) credits Pharmacists: 1.25 contact hours (0.125 CEUs) Released: October 19, 2020 Expired: October 18, 2021

Interactive algorithm tool with NCCN Guidelines® recommendations for Management of Immune Checkpoint Inhibitor–Related Toxicities v1.2020, from CCO

Released: October 16, 2020

Download this slideset from Clinical Care Options, to see the latest data on first-line immunotherapy treatment options for patients with advanced HCC.

Ghassan K. Abou-Alfa, MD, MBA Released: October 14, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.